Glenmark Pharmaceuticals Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 4 Aug 2026 | Market Cap: ₹63.7K Cr
FY '26 revenue growth guidance is 10% to 12%. - Strong growth expected in ROW (Rest of World) and Europe, with ROW growing 10+% in FY '25 and expected to accelerate. - Significant launches in India planned, including BeiGene launches (tislelizumab and zanubrutinib) in early Q1 FY '26. - U.S. Glenmark Pharmaceuticals is targeting a revenue growth of 10% to 12% for FY '26. - EBITDA margin guidance is set between 19% to 20%, driven by new product launches such as RYALTRIS and two major U.S.
From Glenmark Pharmaceuticals Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹2,318
Market Cap
₹63.7K Cr
P/E Ratio
20.4
Glenmark Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹3.9K Cr, net profit ₹403 Cr.
Full financials →📊 Revenue & Sales Performance
- →FY '26 revenue growth guidance is 10% to 12%.
- →Strong growth expected in ROW (Rest of World) and Europe, with ROW growing 10+% in FY '25 and expected to accelerate.
- →Significant launches in India planned, including BeiGene launches (tislelizumab and zanubrutinib) in early Q1 FY '26.
- →U.S. launches in H2 FY '26, including Flovent approval expected end of Q2 and nasal spray launch in H2.
- →RYALTRIS sales expected to cross $100 million in FY '26, up from $80 million in FY '25.
- →India business growth expected to strengthen after bottoming out in diabetes; other segments like cardio, derm, and respiratory growing well.
- →IGI innovation spend around $70 million annually for next 3 years, to be self-funded post-licensing deal.
- →EBITDA margin guidance of 19% to 20%, supported by new product launches and R&D efficiencies.
📈 Profitability & Margins
- →Glenmark Pharmaceuticals is targeting a revenue growth of 10% to 12% for FY '26.
- →EBITDA margin guidance is set between 19% to 20%, driven by new product launches such as RYALTRIS and two major U.S. launches in H2 FY '26.
- →Free cash flow generation is expected to be between INR 300 crores to INR 400 crores, post interest and dividend payments.
- →Margin improvement is supported by operational efficiencies, controlled R&D spend (~6-7% of sales), and resolution of manufacturing plant issues.
- →Innovation entity IGI’s $70 million annual investment is expected to be self-sustaining post a licensing deal, which will further improve consolidated margins.
- →Market expansion in India, Europe, and Rest of World (ROW) with growth in derm, cardio, respiratory, and oncology pipelines.
- →Overall EPS and profit growth expected to benefit from margin expansion and stable revenue growth, with management to provide more granularity in upcoming analyst meets.
🏗️ Capital Expenditure Plans
- →Monroe plant: $150 million investment remains, mainly in injectable lines and utilities. Goal is to get the plant operational with good filings expected (Page 17).
- →IGI investment: Approximately $70 million annual investment expected over next 3 years, covering clinical trial costs and R&D. After a licensing deal, IGI is expected to be self-sustaining with no further investments needed from Glenmark (Pages 10, 7, 6).
- →Asset additions in FY '25: Total INR 698 crores added; INR 309 crores in Q4 alone (INR 226 crores tangible, INR 84 crores intangible) (Page 6).
- →Planning to transfer some CMC activities to contract development and manufacturing organizations for cost efficiency (Page 15).
- →No large expansions in sales force currently planned, existing workforce to drive growth (Page 14).
💰 Fundraising & Capital Structure
- →Glenmark Pharmaceuticals currently has net debt of around INR 489 crores as of March 2025.
- →There is no explicit mention of any planned new fundraising through debt or equity in the provided transcript.
- →The company has indicated that post-closing a licensing deal with IGI (Innovative Genomics Institute), IGI will be self-sustaining for at least the next 3-4 years without requiring additional investment from Glenmark.
- →Glenmark expects that the licensing deal will cover IGI's expenditure of about $70 million per year.
- →No specific plans for raising new debt or equity are mentioned; the focus is on operational cash generation guided at INR 300 to 400 crores and funding innovation through licensing deals rather than new fundraising rounds.
📋 Order Book & Pipeline
- →The transcript from Glenmark Pharmaceuticals' Q4 FY '25 earnings call does not explicitly provide detailed figures on the current or expected order book or pending orders.
- →However, there is strong emphasis on upcoming launches and market opportunities:
- → - Multiple filings in the U.S. in Q2 FY'26 including 3 MDI (metered-dose inhaler) filings and 2-3 nasal sprays.
- → - Launch of BeiGene in-licensed assets (tislelizumab and a BTK product) with significant market potential in India ($200 million+ PD-1/PD-L1 market).
- → - Continued growth in India with RYALTRIS expected to cross $100 million in sales for FY '26.
- → - Discussions indicate ongoing advanced talks and expected quick closure on the ISB 2001 licensing deal, projected to be transformational.
- →Overall, the company demonstrates a healthy pipeline with multiple launches and licensing deals expected to drive future order flow and revenue growth.
Key Metrics
Continue your research
What Glenmark Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Biocon (Q4 FY25)
FY'25 saw a consolidation and transition phase setting up for accelerated growth, with a 10% YoY increase in revenue and 16% YoY growth in core EBITDA (Page…
- Natural Capsules (Q4 FY25)
196 crore, implying about Rs. Key concall takeaways from Natural Capsules Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Laurus Labs (Q4 FY25)
Capex of around INR1,000 crore planned for FY26 primarily to expand CDMO/CMO capacities, with minimal increase in debt. Key concall takeaways from Laurus Labs…
- Wockhardt Ltd (Q4 FY25)
EBITDA growth: Recorded a 67% increase in the last year, with EBITDA margins expanding by 500 basis points from 9% to 14%. Key concall takeaways from Wockhardt…
Frequently Asked Questions
What were Glenmark Pharmaceuticals Ltd Q4 FY25 results?
FY '26 revenue growth guidance is 10% to 12%. - Strong growth expected in ROW (Rest of World) and Europe, with ROW growing 10+% in FY '25 and expected to accelerate. - Significant launches in India planned, including BeiGene launches (tislelizumab and zanubrutinib) in early Q1 FY '26. - U.S. Glenmark Pharmaceuticals is targeting a revenue growth of 10% to 12% for FY '26. - EBITDA margin guidance is set between 19% to 20%, driven by new product launches such as RYALTRIS and two major U.S.
What is Glenmark Pharmaceuticals Ltd share price analysis?
Glenmark Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹63,749 Cr. Investors should review the full earnings analysis for detailed insights.
Is Glenmark Pharmaceuticals Ltd planning capital expenditure?
Monroe plant: $150 million investment remains, mainly in injectable lines and utilities.
Keep Glenmark Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.